| Summary: | The CADTH Canadian Drug Expert Committee recommends that semaglutide be reimbursed for the treatment of type 2 diabetes mellitus to improve glycemic control, if the following conditions are met: Initiation Criteria: 1. Adult patients diagnosed with type 2 diabetes mellitus with inadequate glycemic control. Administration Criteria: 1. In combination with metformin alone, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control. 2. Semaglutide should not be reimbursed for use as add-on therapy to metformin and another antihyperglycemic drug. Pricing Conditions: 1. Drug plan costs for semaglutide should not exceed the drug plan costs of the least costly currently reimbursed drug used when metformin alone is insufficient to achieve glycemic control in the treatment of patients with type 2 diabetes mellitus
|
|---|